ClinicalTrials.gg
CompletedNCT01738477Updated Jun 6, 2018Results posted

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

A Phase 3 interventional study of Boostrix in Tetanus, Acellular Pertussis and Diphtheria, sponsored by GlaxoSmithKline. Completed at 20 sites in United States. Open to participants aged 19 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Non-randomized
Ages
19 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.

Enrollment
19th of 22
165 · median 554
Started
2013
with 1 other
Phase 3
12 of 22
none open now
Registered
14th of 22
by date
Lead sponsor
18 of 22
GlaxoSmithKline

Among the 22 studies testing boostrix in Tetanus, this one is the 19th largest by enrollment, is one of 2 that started in 2013, is one of 12 in phase 3, and was the 14th registered.

Tetanus

318 studies on the registry are indexed under Tetanus; 29 are open to participants now.

Browse Tetanus studies →

Open to participants now

2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About boostrix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing boostrix in Tetanus, or all of them as a file.
02

Study summary

The purpose of this follow-up study is to evaluate the persistence of antibodies against all the vaccine antigens 10 years after booster vaccination with either Tdap or Td, and also to assess immunogenicity and safety of another dose of Boostrix, administered in this study. This protocol posting deals with objectives and outcome measures of the extension phase. The objectives and outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00109330).

Read the detailed description

Subjects were previously vaccinated with either Boostrix or a control Td vaccine in study NCT00109330. Only subjects who were part of the primary study will be invited to participate in this study. All subjects will receive a single dose of Boostrix at Visit 1 (Day 0) and subjects will be observed till Visit 2 (Day 30) for safety in terms of solicited adverse events (during 4 days post vaccination), unsolicited adverse events (during 31 days post vaccination) and serious adverse event (during the trial period). A blood sample will be collected from all subjects before vaccination (Visit 1) and one month after vaccination (Visit 2) for antibodies estimation.

This summary has been updated following Protocol amendment 2 dated 03 October 2013. The protocol is being amended to facilitate enrolment by:

    • Extending the window period for re-vaccination from ± 6 months to ± 300 days from the Year 10 time point.
    • Extending the recruitment period from 6 months to 14 months. The format of non-inferiority criterion of the first co-primary objective has been updated to keep it aligned with the format of non-inferiority criterion of the second co-primary objective.
03

Conditions studied

  • Tetanus
  • Acellular Pertussis
  • Diphtheria

Browse trials for

Keywords

  • Booster
  • Tdap
  • Immunogenicity
  • Repeat dose
  • Safety
  • BoostrixTM
  • Persistence
04

Who can participate

Ages eligible
19 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visit).
  • Subjects who have received a dose of Tdap or Td vaccines 10 years (+/-300 days) back, in study NCT00109330.
  • Written obtained from the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the vaccine dose.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs within six months prior to the booster vaccine dose . For , this will mean prednisone (≥ 20 mg/day (for adult subjects), or equivalent. Inhaled and topical steroids are allowed.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 31 days after the dose of vaccine, with the exception of Influenza vaccine which is allowed throughout the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
  • Previous vaccination against diphtheria, tetanus or pertussis since the last dose received in the Study NCT00109330.
  • History of diphtheria, tetanus or pertussis diseases following the receipt of booster dose in the Study NCT00109330.
  • Severe allergic reaction (e.g. anaphylaxis) after previous administration of any tetanus toxoid, diphtheria toxoid, or pertussis-antigen containing vaccines, or any component of Boostrix.
  • to latex.
  • Encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) of unknown etiology occurring within 7 days following previous vaccination with pertussis-containing vaccine.
  • History of any neurological disorders or seizures.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 99.5°F for oral, axillary or tympanic route, or ≥ 100.4°F for rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the booster dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions up to 1 month post-vaccination.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Boostrix Group 2

    Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who were randomized to the Lot A, Lot B or Lot C groups in study NCT00109330, received a second dose of Boostrix in this study.

    Biological: Boostrix

  • Active comparator
    Boostrix Group 1

    Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who received Massachusetts Public Health Biologic Laboratories combined tetanus and diphtheria vaccine in study NCT00109330, received the first dose of Boostrix in this study.

    Biological: Boostrix

Interventions

  • BiologicalBoostrix

    Single dose intramuscular administration.

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).

    A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)

    Time frame: At Month 1

  2. Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).

    Concentrations were expressed in geometric mean concentrations (GMCs).

    Time frame: At Month 1

Secondary outcomes

  1. Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).

    A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)

    Time frame: At Month 0

  2. Number of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off.

    The cut-off of the assay was ≥ 1.0 IU/mL.

    Time frame: At Month 0 and Month 1

  3. Anti-D and Anti-T Antibody Concentrations.

    Concentrations were expressed as GMCs.

    Time frame: At Month 0 and Month 1

  4. Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).

    Concentrations were expressed in geometric mean concentrations (GMCs).

    Time frame: At Month 0

  5. Number of Subjects With a Booster Response to Anti-D and Anti-T.

    Booster response to anti-D and anti-T antigens was defined as: * for initially seronegative subjects with pre-booster antibody concentration below 0.1 IU/mL, an increase of at least four times 0.1 IU/mL one month after vaccination, * for initially seropositive subjects with pre-booster antibody concentration ≥ 0.1 IU/mL, an increase of at least four times the pre-booster antibody concentration one month after vaccination.

    Time frame: At Month 1

  6. Number of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN.

    Booster response to pertussis antigens was defined as: * for initially seronegative subjects (pre-booster antibody concentration below the assay cut-off) with an increase of at least four times the assay cut-off one month after vaccination; * for initially seropositive subjects with anti-body concentration \< four times the assay cut-off with an increase of at least four times the pre-booster antibody concentration one month after vaccination; * for initially seropositive subjects with anti-body concentration ≥ four times the assay cut-off with an increase of at least two times the pre-booster antibody concentration one month after vaccination.

    Time frame: At Month 1.

  7. Number of Subjects With Solicited Local Symptoms.

    The solicited local symptoms assessed were Pain, Redness and Swelling. Any = any solicited local symptom regardless of intensity.

    Time frame: During the 4 days (Day 0 - 3) follow-up period after vaccination.

  8. Number of Subjects With Solicited General Symptoms.

    The solicited local symptoms assessed were Fatigue, Gastrointestinal, Headache and Fever. Any = any solicited general symptom regardless of intensity.

    Time frame: During the 4 days (Day 0 - 3) follow-up period after vaccination.

  9. Number of Subjects With Unsolicited Adverse Events (AEs).

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.

    Time frame: During the 31 days (Day 0 - 30) after vaccination.

  10. Number of Subjects With Serious Adverse Events (SAEs).

    SAEs assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: From Day 0 to 31 days post-vaccination.

07

Results

Posted Dec 27, 2017

Participant flow

Participant flow — Overall Study
MilestoneBoostrix Group 1Boostrix Group 2
Started37128
Completed36124
Not completed14
Withdrew: Lost to follow-up14

Outcome measures

PrimaryNumber of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).

A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)

Time frame:
At Month 1
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).
ParticipantsBoostrix Group 1Boostrix Group 2
Anti-D35115
Anti-T35115
Statistical analysis
  • Boostrix Group 1 vs Boostrix Group 2 · Mean difference (final values): 0 · 95% CI -3.25 to 9.95
  • Boostrix Group 1 vs Boostrix Group 2 · Mean difference (final values): 0 · 95% CI -3.25 to 9.95
PrimaryAntibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).

Concentrations were expressed in geometric mean concentrations (GMCs).

Time frame:
At Month 1
Reported as:
Geometric mean · IU/mL
Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).
IU/mLBoostrix Group 1Boostrix Group 2
anti-PT66.2 (50.8 to 86.2)87.3 (74.5 to 102.4)
anti-FHA336.2 (250.0 to 452.2)290.5 (252.5 to 334.2)
anti-PRN425.5 (281.9 to 642.3)463.3 (390.8 to 549.3)
SecondaryNumber of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).

A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)

Time frame:
At Month 0
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).
ParticipantsBoostrix Group 1Boostrix Group 2
Anti-D35115
Anti-T35115
SecondaryNumber of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off.

The cut-off of the assay was ≥ 1.0 IU/mL.

Time frame:
At Month 0 and Month 1
Reported as:
Count of participants · Participants
Number of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off.
ParticipantsBoostrix Group 1Boostrix Group 2
Anti-D at Month 02370
Anti-D at Month 134115
Anti-T at Month 02786
Anti-T at Month 135115
SecondaryAnti-D and Anti-T Antibody Concentrations.

Concentrations were expressed as GMCs.

Time frame:
At Month 0 and Month 1
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations.
IU/mLBoostrix Group 1Boostrix Group 2
Anti-D at Month 01.6 (1.1 to 2.3)1.6 (1.3 to 2.1)
Anti-D at Month 16.8 (5.4 to 8.6)6.0 (5.3 to 6.9)
Anti-T at Month 01.8 (1.4 to 2.4)1.8 (1.5 to 2.2)
Anti-T at Month 19.9 (7.9 to 12.5)9.7 (8.5 to 11.0)
SecondaryAntibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).

Concentrations were expressed in geometric mean concentrations (GMCs).

Time frame:
At Month 0
Reported as:
Geometric mean · IU/mL
Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).
IU/mLBoostrix Group 1Boostrix Group 2
anti-PT5.3 (3.4 to 8.2)9.9 (8.1 to 12.2)
anti-FHA21.7 (13.4 to 35.4)36.9 (31.5 to 43.3)
anti-PRN27.8 (13.7 to 56.3)71.6 (56.7 to 90.6)
SecondaryNumber of Subjects With a Booster Response to Anti-D and Anti-T.

Booster response to anti-D and anti-T antigens was defined as: * for initially seronegative subjects with pre-booster antibody concentration below 0.1 IU/mL, an increase of at least four times 0.1 IU/mL one month after vaccination, * for initially seropositive subjects with pre-booster antibody concentration ≥ 0.1 IU/mL, an increase of at least four times the pre-booster antibody concentration one month after vaccination.

Time frame:
At Month 1
Reported as:
Count of participants · Participants
Number of Subjects With a Booster Response to Anti-D and Anti-T.
ParticipantsBoostrix Group 1Boostrix Group 2
Anti-D1447
Anti-T2164
SecondaryNumber of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN.

Booster response to pertussis antigens was defined as: * for initially seronegative subjects (pre-booster antibody concentration below the assay cut-off) with an increase of at least four times the assay cut-off one month after vaccination; * for initially seropositive subjects with anti-body concentration \< four times the assay cut-off with an increase of at least four times the pre-booster antibody concentration one month after vaccination; * for initially seropositive subjects with anti-body concentration ≥ four times the assay cut-off with an increase of at least two times the pre-booster antibody concentration one month after vaccination.

Time frame:
At Month 1.
Reported as:
Count of participants · Participants
Number of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN.
ParticipantsBoostrix Group 1Boostrix Group 2
Anti-PT33106
Anti-FHA34104
Anti-PRN2979
SecondaryNumber of Subjects With Solicited Local Symptoms.

The solicited local symptoms assessed were Pain, Redness and Swelling. Any = any solicited local symptom regardless of intensity.

Time frame:
During the 4 days (Day 0 - 3) follow-up period after vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms.
ParticipantsBoostrix Group 1Boostrix Group 2
Any Pain2197
Any Redness1547
Any Swelling730
SecondaryNumber of Subjects With Solicited General Symptoms.

The solicited local symptoms assessed were Fatigue, Gastrointestinal, Headache and Fever. Any = any solicited general symptom regardless of intensity.

Time frame:
During the 4 days (Day 0 - 3) follow-up period after vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms.
ParticipantsBoostrix Group 1Boostrix Group 2
Any Fatigue838
Any Gastrointestinal Symptoms111
Any Headache840
Any Fever13
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs).

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.

Time frame:
During the 31 days (Day 0 - 30) after vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs).
ParticipantsBoostrix Group 1Boostrix Group 2
Number of Subjects With Unsolicited Adverse Events (AEs).1033
SecondaryNumber of Subjects With Serious Adverse Events (SAEs).

SAEs assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
From Day 0 to 31 days post-vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs).
ParticipantsBoostrix Group 1Boostrix Group 2
Number of Subjects With Serious Adverse Events (SAEs).00

Adverse events

Collected over Solicited local/general symptoms: during the 4-days (Days 0-3) post-vaccination period; Unsolicited AE(s): during the 31-day (Days 0-30) post-vaccination period; SAE(s): from Month 0 to Month 1.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Boostrix Group 10/37 (0%)0/37 (0%)30/37 (81.1%)
Boostrix Group 20/128 (0%)0/128 (0%)107/128 (83.6%)
Most frequent other events
Most frequent other events
EventBoostrix Group 1Boostrix Group 2
PainGeneral disorders21/3797/128
ErythemaSkin and subcutaneous tissue disorders15/3747/128
HeadacheNervous system disorders11/3746/128
FatigueGeneral disorders8/3738/128
SwellingGeneral disorders7/3730/128
Gastrointestinal disorderGastrointestinal disorders1/3711/128
DysmenorrhoeaReproductive system and breast disorders2/372/128
MyalgiaMusculoskeletal and connective tissue disorders2/371/128

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Boostrix Group 1Boostrix Group 2Total
Mean23.3 ± 2.423.5 ± 2.123.5 ± 2.1
Sex: Female, Male
Sex: Female, Male(Participants)Boostrix Group 1Boostrix Group 2Total
Female185775
Male197190
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Boostrix Group 1Boostrix Group 2Total
Black167
Oriental011
Other5712
White/caucasian31114145
08

Study locations

20 sites
  • GSK Investigational Site
    Mesa, Arizona 85213, United States
  • GSK Investigational Site
    Tempe, Arizona 85283, United States
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Fullerton, California 92835, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    Golden, Colorado 80401, United States
  • GSK Investigational Site
    Norwich, Connecticut 06360, United States
  • GSK Investigational Site
    Jacksonville, Florida 32209, United States
  • GSK Investigational Site
    Chicago, Illinois 60614, United States
  • GSK Investigational Site
    Bardstown, Kentucky 40004, United States
  • GSK Investigational Site
    Woburn, Massachusetts 01801, United States
  • GSK Investigational Site
    Omaha, Nebraska 68131, United States
  • GSK Investigational Site
    East Setauket, New York 11733, United States
  • GSK Investigational Site
    Cleveland, Ohio 44109, United States
  • GSK Investigational Site
    Cleveland, Ohio 44121, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16505, United States
  • GSK Investigational Site
    Upper Saint Clair, Pennsylvania 15241, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84109, United States
  • GSK Investigational Site
    South Jordan, Utah 84095, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Apr 2014, 14 months.

Results were first posted in Dec 2017, 3 years 8 months after primary completion. A results delay was requested in Apr 2015.

Of 55 industry-sponsored phase 3 interventional studies under Tetanus, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's 14 months is above that.

Counting every sponsor, half of 56 studies reached it within 12 months; a quarter within 6 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2012
First posted
Nov 30, 2012
StartActual
Jan 31, 2013
Primary completionActual
Apr 2, 2014
CompletionActual
Apr 2, 2014
Results delay requested
Apr 2, 2015
Results first posted
Dec 27, 2017
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01738477
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 30, 2012
Start date
Jan 31, 2013
Primary completion
Apr 2, 2014
Completion
Apr 2, 2014
Results posted
Dec 27, 2017
Last update
Jun 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boostrix

Start the discussion